Capricor Therapeutics Inc (CAPR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.24 is considered Undervalued compared with the five-year average of -5.48. The fair price of Capricor Therapeutics Inc (CAPR) is between 37.08 to 49.57 according to relative valuation method. Compared to the current price of 26.86 USD , Capricor Therapeutics Inc By Undervalued By 27.55%.

Relative Value

Fair Zone

37.08-49.57

Current Price：26.86

27.55%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Capricor Therapeutics Inc (CAPR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Capricor Therapeutics Inc (CAPR) has a current Price-to-Book (P/B) ratio of 15.43. Compared to its 3-year average P/B ratio of 9.45, the current P/B ratio is approximately 63.34% higher. Relative to its 5-year average P/B ratio of 7.40, the current P/B ratio is about 108.41% higher. Capricor Therapeutics Inc (CAPR) has a Forward Free Cash Flow (FCF) yield of approximately -4.67%. Compared to its 3-year average FCF yield of -15.58%, the current FCF yield is approximately -70.03% lower. Relative to its 5-year average FCF yield of -11.72%, the current FCF yield is about -60.16% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CAPR competitors is 113.60, providing a benchmark for relative valuation. Capricor Therapeutics Inc Corp (CAPR.O) exhibits a P/S ratio of 20.24, which is -82.19% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CAPR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CAPR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CAPR currently overvalued or undervalued?

Capricor Therapeutics Inc (CAPR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.24 is considered Undervalued compared with the five-year average of -5.48. The fair price of Capricor Therapeutics Inc (CAPR) is between 37.08 to 49.57 according to relative valuation method. Compared to the current price of 26.86 USD, Capricor Therapeutics Inc is Undervalued By 27.55%.

What is Capricor Therapeutics Inc (CAPR) fair value?

CAPR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Capricor Therapeutics Inc (CAPR) is between 37.08 to 49.57 according to relative valuation method.

How does CAPR's valuation metrics compare to the industry average?

The average P/S ratio for CAPR's competitors is 113.60, providing a benchmark for relative valuation. Capricor Therapeutics Inc Corp (CAPR) exhibits a P/S ratio of 20.24, which is -82.19% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for Capricor Therapeutics Inc (CAPR) as of Mar 03 2026?

As of Mar 03 2026, Capricor Therapeutics Inc (CAPR) has a P/B ratio of 15.43. This indicates that the market values CAPR at 15.43 times its book value.

What is the current FCF Yield for Capricor Therapeutics Inc (CAPR) as of Mar 03 2026?

As of Mar 03 2026, Capricor Therapeutics Inc (CAPR) has a FCF Yield of -4.67%. This means that for every dollar of Capricor Therapeutics Inc's market capitalization, the company generates -4.67 cents in free cash flow.

What is the current Forward P/E ratio for Capricor Therapeutics Inc (CAPR) as of Mar 03 2026?

As of Mar 03 2026, Capricor Therapeutics Inc (CAPR) has a Forward P/E ratio of -26.54. This means the market is willing to pay $-26.54 for every dollar of Capricor Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Capricor Therapeutics Inc (CAPR) as of Mar 03 2026?

As of Mar 03 2026, Capricor Therapeutics Inc (CAPR) has a Forward P/S ratio of 20.24. This means the market is valuing CAPR at $20.24 for every dollar of expected revenue over the next 12 months.

CAPR Valuation